ASCO 2024: Rogel Recap of the 2024 ASCO Annual Meeting

Media contact: Eric Olsen, 734-764-2220   |  Patients may contact Cancer AnswerLine™ 800-865-1125

The 2024 American Society of Clinical Oncology Annual Meeting was held at McCormick Place, downtown Chicago, May 31—June 4.

During the five-day event, Rogel Cancer Center researchers moderated sessions, gave presentations, and shared research posters to an audience of more than 40,000 cancer researchers from around the globe. Here are some highlights from this year’s meeting:

• Norah Lynn Henry, M.D., Ph.D., professor and interim division chief for Hematology/Oncology co-led a panel discussion on Breast Cancer along with Puneet Singh, M.D., FACS, assistant professor at MD Anderson Cancer Center. The two panelists were Joyce O'Shaughnessy, M.D., Baylor University Medical Center; and Jane Meisel, M.D., Winship Canter Institute of Emory University.
• Christopher Lao, M.D., adjunct clinical professor of hematology/oncology, talked about the latest advancements shaping the present and future of NSCLC treatment in his talk titled “Innovative Therapy Options and Research to Meet Diverse Patient Needs Across NSCLC” at the Industry Experts Theater.
• Professor of health management and policy, Jennifer Griggs, M.D., M.P.H., presented a talk titled “Building the Foundation: Principles from Professional Coaching” at the Training Program Director’s Breakfast.
• Kenneth Warner, Ph.D., Avedis Donabedian Distinguished University Professor Emeritus of Public Health; dean emeritus, U-M School of Public Health, led a panel discussion called “The Place of E-Cigarettes in Smoking Cessation Treatment and Policy: Approaches From Around the World”, which reviewed evidence regarding the individual health risks of e-cigarettes as compared to conventional combustible cigarettes. Panelists included Ann McNeil, Ph.D., King's College London; and Ben Youdan of Youdan Consulting.
• Co-Director of Integrative Medicine, Suzanna Zick, N.D., M.P.H., was part of a panel discussion that discussed “An Update on the Fatigue SIO/ASCO Guidelines.” The session reviewed updated evidence-based guidelines from the Society of Integrative Oncology and ASCO regarding the use of integrative medicine to alleviate fatigue and manage anxiety and depression during and after treatment. Panel moderator was Ashwin Mehta, M.D., Memorial Healthcare System; and Zick was joined on the panel by Richard T. Lee, M.D., City of Hope.

Ulka N. Vaishampayan, M.D., MBBS (left) and Erin Cobain, M.D. make presentations at the 2024 ASCO conference.
Photo credit: Michigan Medicine

• Ulka N. Vaishampayan, M.D., MBBS, clinical professor in medical oncology, shared updated results from “Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors”.
• Erin Cobain, M.D., assistant professor, medical oncology, presented “Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.” Cobain and team reviewed previous study data which suggests that breast cancer patients with a specific tumor biomarker could benefit from a combination of chemo- and immunotherapies.

Several Rogel researchers presented posters at ASCO this year. Here’s a sampling:

• DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study. Sreenivasa R Chandana, M.D., Ph.D.
• A novel, noninvasive, multimodal screening test for the early detection of precancerous lesions and colorectal cancers using an artificial intelligence–based algorithm. D. Kim Turgeon, M.D.
• Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04). Vaibhav Sahai, MBBS, M.S.
• Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial. Charles B Nguyen, M.D.
• Predictors of long-term prostate cancer mortality in men continuing prostate-specific antigen screening after age 70. Dana H. Chung
• Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC). Charles B Nguyen, M.D.
• Clinical outcomes in salivary adenoid cystic carcinoma. Prarthana Dalal, M.D., Ph.D.
• Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial. Paul Swiecicki, M.D.
• Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy. Francis P. Worden, M.D.
• Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Yasmin Karimi, M.D.
• Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Yasmin Karimi, M.D.
• Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study. Henry Dumke, M.D.

Steven Katz, M.D., M.P.H. and Allison Kurian, M.D., M.Sc.
Photo credit: Michigan Medicine

• Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer. Steven Jay Katz, M.D., M.P.H.
• Association of social determinants of health (SDH), allostatic load (AL) and incident cancers in the multi-ethnic study of atherosclerosis (MESA). Ruth C. Carlos, M.D., FACR
• Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy. Daniel Louis Hertz, Pharm.D., Ph.D.